CohBar (CohBar) Insider Ownership : 7.99 % (As of Jun. 06, 2024)

View and export this data going back to 2015. Start your Free Trial

What is CohBar Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CohBar's insider ownership is 7.99%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CohBar's Institutional Ownership is 0.04%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CohBar's Float Percentage Of Total Shares Outstanding is 96.92%.

CohBar Insider Ownership Historical Data

The historical data trend for CohBar's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CohBar Insider Ownership Chart

CohBar Historical Data

The historical data trend for CohBar can be seen below:

	2021-11-30	2021-12-31	2022-01-31	2022-02-28	2022-03-31	2022-04-30	2022-05-31	2022-06-30	2022-07-31	2022-08-31
Insider Ownership	7.96	7.96	7.96	7.96	7.80	7.80	7.80	7.80	7.80	7.99

CohBar Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

CohBar (CohBar) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CohBar Inc (OTCPK:CWBR) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

1455 Adams Drive, Suite 2050, Menlo Park, CA, USA, 94025

Website

https://www.cohbar.com

CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria-based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drugs such as CB4209 and CB4211, SHLP-6, SHLP-2, and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operations of the group functioned through the region of the United States.

Executives

Stephanie Tozzo	director	C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Misha Petkevich	director	C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joanne Yun	director	C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joseph J. Sarret	director, officer: Chief Executive Officer	C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carol Nast	director	C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Kenneth C Cundy	officer: Chief Scientific Officer	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jeffrey Francis Biunno	officer: CFO, Treasurer and Secretary	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Steven B Engle	officer: Chief Executive Officer	C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
David Greenwood	director	230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Phyllis Gardner	director	618 MIRADA AVENUE, STANFORD CA 94305
Philippe Calais	director	C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
John Amatruda	director	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Simon Allen	officer: Chief Executive Officer	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Albion Fitzgerald	director	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jon Leland Stern	director, officer: Chief Executive Officer	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025